DNA-Linked Double-Stranded RNA for Statin-Resistant Hypercholesterolemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cardiovascular diseases associated with elevated LDL-C levels, such as familial hypercholesterolemia, are limited by statin resistance and the need for alternative, more effective treatments that can safely and specifically target cardiovascular disease genes.
Innovation Solution
A nucleic acid molecule comprising a double-stranded inhibitory RNA with a covalently linked single-stranded DNA at its 5' end, forming a hairpin structure, which targets cardiovascular disease genes without requiring modified nucleotides, enhancing pharmacodynamics and pharmacokinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are used to lower LDL-C levels, then cholesterol synthesis is blocked, but statin resistance develops over time reducing effectiveness
Solution Approach 1:
The patent uses double-stranded RNA as an intermediary molecule to deliver gene-specific silencing signals to target cardiovascular disease genes. This RNA-based mediator bypasses the metabolic pathway targeted by statins (HMG-CoA reductase) and directly interferes with gene expression at the mRNA level, thereby overcoming statin resistance while maintaining therapeutic effectiveness for long-term LDL-C management.
2Reliability
If alternative therapeutic agents are combined with statins, then LDL-C levels are further reduced, but treatment complexity increases
Solution Approach 1:
The patent extracts and targets specific gene sequences responsible for cardiovascular disease using double-stranded RNA molecules. By isolating the genetic target (mRNA) and applying gene silencing technology directly to it, the invention simplifies the therapeutic approach compared to combination drug therapy, achieving effective LDL-C reduction through a single targeted mechanism rather than multiple drugs acting on different pathways.
3Measurement precision
If double-stranded RNA is used to silence gene expression, then cardiovascular disease genes are targeted specifically, but delivery and stability challenges arise
Solution Approach 1:
The patent employs composite nucleic acid structures consisting of double-stranded RNA molecules with specific sequence compositions designed to enhance stability. The complementary base pairing in the double-stranded structure provides inherent stability, while the specific nucleotide sequences are selected to resist degradation. This composite approach maintains high gene targeting precision through sequence specificity while improving molecular stability for effective delivery and sustained therapeutic action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nucleic acid molecule effectively silences gene expression, potentially reducing side effects and providing sustained therapeutic benefits for cardiovascular diseases like hypercholesterolemia and atherosclerosis.
Implementation Method 1
the single stranded DNA molecule comprises a nucleotide sequence that is adapted over at least part of its length to anneal by complementary base pairing to a part of said single stranded DNA to form a double stranded DNA structure
Data Source
AI summary
This disclosure relates to a nucleic acid comprising a double stranded RNA molecule comprising sense and antisense strands and further comprising a single stranded DNA molecule covalently linked to at least the 5′ end of either the sense or antisense RNA part of the molecule wherein the double stranded inhibitory RNA targets genes associated with cardiovascular disease in the treatment hypercholesterolemia and diseases associated with hypercholesterolemia such as cardiovascular disease.